Compliance Tool · OIG Enforcement

Corporate Integrity Agreements Dashboard

Active HHS OIG Corporate Integrity Agreements entered 2023–2026, with violation summaries, the material compliance obligations each one imposes, and a plain read on what it means for your own program.

Source: OIG CIA Browser ↗  ·  Compiled as of July 19, 2026  ·  66 agreements  ·  2023–2026  ·  active CIAs effective in this window

66 agreements shown
66CIAs (2023–2026)
~$2.70BTotal settlements
$650MLargest settlement (combined)
~68%False Claims Act
5 yr / 3 yrTypical CIA terms

Cross-CIA takeaways for your organization

Patterns across the 2023–2026 agreements: what to audit, tighten, and watch for in your own compliance program.

Whistleblowers are your early-warning system
Most of these cases were initiated by employee, competitor, or patient whistleblowers under the False Claims Act's qui tam provisions. A robust internal disclosure program (with genuine non-retaliation protections) is the best way to surface problems before the DOJ does. The FCA's relator share creates a powerful incentive for employees to go to the government when they can't reach leadership.
Relevant: Kinex, Advanced Urology, Modern Nuclear, Semler, Fresno Community, Matrix, and others
Medical-necessity documentation is a billing matter
Multiple CIAs involve billing for tests or procedures that were medically unnecessary or not performed. Every ordered test or procedure needs a contemporaneous clinical rationale in the record. High-frequency tests (urine drug testing, respiratory panels, wound-care procedures) are OIG audit priorities; audit your own ordering patterns against clinical benchmarks before regulators do.
Relevant: Bethany, Dr. Malone, VHS Holdings, Advanced Urology, Kinex, Patient Choice, Semler
Any financial arrangement with a referring physician requires FMV
Several CIAs involve improper financial arrangements with physicians, from above-FMV supervision fees (Modern Nuclear) to physician bonuses for referrals (Fresno) to kickbacks disguised as marketing fees (Patient Choice). All compensation to physicians who can refer (employment, co-management, supervision, hospitality, technology subsidies) must be at fair market value, commercially reasonable, and documented before execution.
Relevant: Modern Nuclear, Fresno Community Hospital, Patient Choice Labs, NUWAY
Risk-adjustment coding must match the clinical record
Matrix Medical Network ($36.5M) submitted diagnosis codes to Medicare Advantage where the assessment forms didn't contain enough clinical information to support them. For any MA plan, ACO, or value-based contract where diagnosis coding affects payment, each submitted code must be supported by the contemporaneous record. Retrospective coding enhancements without documentation are a known OIG and DOJ target.
Relevant: Community Care Health Network (Matrix)
Quality-of-care failures are also FCA violations
Several nursing-home and disability-services CIAs show that accepting Medicare/Medicaid payment while providing objectively substandard care (understaffing, neglect, failure to meet minimum standards) is itself a False Claims Act violation under the "worthless services" doctrine: if the care is so deficient it has no value, the claims are false. Staffing adequacy is a billing-compliance matter, not just a quality metric.
Relevant: Center for Disability Services, Moroun/Villa, American Health Foundation, Riverpark/Avamere
Controlled-substance oversight is a federal compliance obligation
Walgreens ($300M) and Dr. Kabakibou ($3.5M) show that pharmacies and physicians face concurrent FCA and Controlled Substances Act liability. Pharmacies must maintain and act on suspicious-prescription monitoring. Physicians must be present when signing controlled-substance prescriptions and document medical necessity for every opioid order. Pre-signed prescription pads are both a CSA violation and a source of false Medicare claims.
Relevant: Walgreen Co, Kamal Kabakibou

This dashboard compiles publicly reported HHS OIG Corporate Integrity Agreements and DOJ press releases, summarized for general compliance-learning purposes. The summaries and lessons are interpretive and may simplify complex settlements. This is not legal advice. Brandon Goulter is not an attorney, and using this dashboard creates no professional advisory relationship. Settlement figures, effective dates, and obligations should be confirmed against the linked OIG pages and CIA documents, and current requirements verified with a licensed attorney before acting. Settlement amounts are civil recoveries except where a case note says otherwise; the largest-settlement figure ($650M, McKinsey) is a combined criminal and civil resolution, of which $323M was the civil False Claims Act portion. Agreement status was verified against the OIG CIA directory as of July 19, 2026; status can change as OIG closes agreements following final-report review. Case summaries and material obligations for each agreement were cross-checked against OIG CIA documents, DOJ press releases, and related court filings as of July 19, 2026.